Travere Therapeutics
TVTX | NASDAQ
$49.70
-$0.95 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$49.50
-$0.20 (-0.40%)
After-hours:
Nov 16, 2026, 7:46 PM ET
Travere Therapeutics Company Profile
Company profile explainedCompany Profile
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Key Executives
| Name | Position |
|---|---|
| Eric Dube | President, Chief Executive Officer & Director |
| Angela Giannantonio | Chief People Officer |
| Christopher Cline | Chief Financial Officer |
| Elizabeth E. Reed | Chief Legal Officer, General Counsel & Secretary |
| Casey Logan | Chief Business Officer |
| Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer |
| Nivi Nehra | Vice President of Corporate Communications & Investor Relations |
| Peter Heerma | Chief Commercial Officer |
| Sandra Calvin | SVP & Chief Accounting Officer |
| William E. Rote | Chief Research Officer |
Travere Therapeutics
| Country | United States |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 497 |
| CEO | Eric Dube |
Contact Details
3611 Valley Centre Drive San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | TVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438533 |
| CUSIP Number | 89422G107 |
| ISIN Number | US89422G1076 |
| SIC Code | 2834 |
Recent News
- 12 hours ago / seekingalpha.comTravere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
- 17 hours ago / seekingalpha.comTravere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy
- 13 days ago / businesswire.comTravere Therapeutics to Participate at Upcoming Investor Conferences
- 14 days ago / seekingalpha.comTravere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
- 14 days ago / zacks.comHere's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
- 14 days ago / marketbeat.comWhat Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
- 14 days ago / zacks.comTravere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- 14 days ago / businesswire.comTravere Therapeutics Reports Third Quarter 2026 Financial Results
- 21 days ago / businesswire.comTravere Therapeutics to Report Third Quarter 2026 Financial Results
- 24 days ago / businesswire.comTravere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Add to Watchlist
Select watchlists to add or remove TVTX